3 TSX Stocks That Could Turn $15,000 Into $150,000

These TSX stocks offer three different opportunities, but each could be a multi bagger in the works.

| More on:
a sign flashes global stock data

Source: Getty Images

Key Points

  • Lightspeed is pivoting to profitable SaaS and payments, growing revenue and margins with $447M cash—potential turnaround if execution continues.
  • Celestica supplies AI hardware, delivering record margins and raised guidance; strong cash flow and buybacks support further upside despite rich valuation.
  • NervGen is a high-risk speculative play with promising spinal-cord drug data but no revenue and limited cash, making outcomes binary.

Imagine it. You buy up some TSX stocks and leave them alone, only to come back a few years later to see that you ended up investing in a 10-bagger. It’s not too crazy to imagine, given that there are already many stocks out there offering up value, and they are already seeing the growth. So today, we’re going to look at three of them.

Lightspeed Commerce

First off, there’s Lightspeed Commerce (TSX:LSPD). This point-of-sale (POS) and e-commerce company has had quite the history, soaring in share price only to come crashing down after a short sale report. Since then, the tech stock has really struggled to come back upwards. Yet these days, LSPD is pivoting from the high-burn tech story into a leaner software-as-a-service (SaaS) and payments model.

During its most recent quarterly report, revenue grew 15% year over year, with the gross margin expanding as well. Annual revenue per user (ARPU) also climbed, with payments penetration rising fast. Meanwhile, it holds $447 million in cash, has low debt, and is nearing profitability. In fact, management remains confident about the future, buying back 12% of shares in full-year 2025. If LSPD keeps it up, this TSX stock could see double-digit growth in the near future.

Celestica

Celestica (TSX:CLS) was another trend beneficiary, but this time in artificial intelligence (AI). The thing is, it’s not exactly an AI stock. Instead, it manufactures the parts that support AI. Arguably, that’s even more important than the big name AI stocks. It’s now morphed from a low-margin contract manufacturer into a leading supplier for hyperscalers and AI hardware.

The second quarter saw record operating margins, with management raising guidance sharply for 2025. In fact, the stock has already risen about 450% in the last year! Given that, you’re not exactly getting value trading at 38 times forward earnings. However, cash flow remains strong, and buybacks continue. All considered, we can see that AI remains a part of our present and future. Therefore, Celestica should remain a prime beneficiary, with the possibility of long-term multi-bagger gains.

NervGen Pharma

Finally we have NervGen Pharma (TSXV:NGEN). This is more of a moonshot, thanks to its position in the pharmaceutical sector. Its NVG-291 drug showed promise during its primary phases, focusing on chronic spinal cord injury, which has no approved therapies. If the results remain positive, this could be a breakthrough in neurology.

The problem? There’s no revenue and finite cash at just $15.7 million, with a $17 million annual burn. There’s now also a high dependence on successful trials, and that can be an extreme binary risk. So yes, if this goes through, NGEN stock could go to the moon. However, it’s a pure speculative ticket out of the three, so perhaps one more to watch for now.

Bottom line

Taken together, these three TSX stocks offer a mix of value, stability, and speculation. LSPD could be a growth turnaround with the cash to execute. Celestica has already rewarded shareholders, but could continue over the next several years. Finally, NervGen is a “what if” stock that could easily surge, but also crash. In any case, all three could potentially be multi-baggers, but remain high risk. So be certain to meet with your financial advisor before considering any investment.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool recommends Lightspeed Commerce. The Motley Fool has a disclosure policy.

More on Tech Stocks

Rocket lift off through the clouds
Tech Stocks

2 Growth Stocks Set to Skyrocket in 2026 and Beyond

Growth stocks like Blackberry and Well Health Technologies are looking forward to leveraging strong opportunities in their respective industries.

Read more »

Happy golf player walks the course
Tech Stocks

The January Reset: 2 Beaten-Down TSX Stocks That Could Stage a Comeback

A January TFSA reset can work best with “comeback” stocks that still have real cash engines, not just hype.

Read more »

investor looks at volatility chart
Tech Stocks

1 Magnificent Canadian Tech Stock Down 38% to Buy and Hold for Decades

Constellation Software is a TSX tech stock that offers significant upside potential to shareholders over the next 12 months.

Read more »

AI concept person in profile
Tech Stocks

Tech’s January Bounce: 2 Canadian Stocks That Could Lead a 2026 Rebound

A January tech bounce can happen fast when fresh money and improving mood push investors back into overlooked Canadian names.

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Stocks Retirees Should Absolutely Love

Discover strategies for managing stocks during retirement, especially in light of market uncertainties and downturns.

Read more »

Canada Day fireworks over two Adirondack chairs on the wooden dock in Ontario, Canada
Tech Stocks

Down 38%, This Magnificent Canadian Stock Could Be the Biggest Bargain on the TSX Today

Constellation Software (TSX:CSU) was a tough hold in 2025, could the new year be a turning point.

Read more »

The letters AI glowing on a circuit board processor.
Tech Stocks

Meet the Canadian Semiconductor Stock Up 150% This Year

Given its healthy growth outlook and reasonable valuation, 5N Plus would be a compelling buy at these levels.

Read more »

money goes up and down in balance
Tech Stocks

1 Magnificent Canadian Stock Down 26% to Buy and Hold Forever

Lightspeed isn’t the pandemic high-flyer anymore and that reset may be exactly what gives patient investors a better-risk, better-price entry…

Read more »